Literature DB >> 26319484

Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation.

Don Hayes1, Sylvester M Black2, Joseph D Tobias3, Stephen Kirkby4, Heidi M Mansour5, Bryan A Whitson2.   

Abstract

BACKGROUND: The influence of varying levels of pulmonary hypertension (PH) on survival in idiopathic pulmonary fibrosis is not well defined.
METHODS: The United Network for Organ Sharing database was queried from 2005 to 2013 to identify first-time lung transplant candidates listed for lung transplantation who were tracked from waitlist entry date until death or censoring to determine the influence of PH on patients with advanced lung disease. Using data for right heart catheterization measurements, mild PH was defined as mean pulmonary artery pressure of 25 mm Hg or more, and severe as 35 mm Hg or more.
RESULTS: Of 6,657 idiopathic pulmonary fibrosis patients, 6,651 were used for univariate analysis, 6,126 for Kaplan-Meier survival function, 6,013 for multivariate Cox models, and 5,186 (mild PH) and 2,014 (severe PH) for propensity score matching, respectively. Univariate Cox proportional hazards analysis found significant differences in survival for mild PH (hazard ratio [HR] 1.689, 95% confidence interval [CI]: 1.434 to 1.988, p < 0.001) and severe PH (HR 2.068, 95% CI: 1.715 to 2.493, p < 0.001). Further assessment by multivariate Cox models identified significant risk for death for mild PH (HR 1.433, 95% CI: 1.203 to 1.706, p < 0.001) and severe PH (HR 1.597, 95% CI: 1.308 to 1.949, p < 0.001). Propensity score matching confirmed the risk for death for mild PH (HR 1.530, 95% CI: 1.189 to 1.969, p = 0.001) and severe PH (HR 2.103, 95% CI: 1.436 to 3.078, p < 0.001).
CONCLUSIONS: The manifestation of PH, even with mild severity, is associated with significantly increased risk for death among patients with idiopathic pulmonary fibrosis awaiting lung transplantation, so referral should be considered early in the disease course.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26319484     DOI: 10.1016/j.athoracsur.2015.06.024

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  16 in total

1.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

2.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Pulmonary hypertension in chronic lung disease and hypoxia.

Authors:  Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 4.  Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

Authors:  Johan van Cleemput; Andrea Sonaglioni; Wim A Wuyts; Monica Bengus; John L Stauffer; Sergio Harari
Journal:  Adv Ther       Date:  2018-12-15       Impact factor: 3.845

5.  Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy.

Authors:  Maria F Acosta; Priya Muralidharan; Carissa L Grijalva; Michael D Abrahamson; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

6.  Effect of Immune Cell Infiltration on Occurrence of Pulmonary Hypertension in Pulmonary Fibrosis Patients Based on Gene Expression Profiles.

Authors:  Feng Zhu; Lili Zuo; Rui Hu; Jin Wang; Zhihua Yang; Xin Qi; Limin Feng
Journal:  Front Med (Lausanne)       Date:  2021-07-07

Review 7.  Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium.

Authors:  Christopher A Thomas; Ryan J Anderson; David F Condon; Vinicio A de Jesus Perez
Journal:  Pulm Ther       Date:  2019-11-29

8.  IPF patients are limited by mechanical and not pulmonary-vascular factors - results of a derivation-validation cohort study.

Authors:  Benjamin D Fox; Yael Shostak; Barak Pertzov; Baruch Vainshelboim; Shimon Itzhakian; Irit Terner; Mordechai R Kramer
Journal:  BMC Pulm Med       Date:  2019-12-11       Impact factor: 3.317

9.  Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist.

Authors:  Priya Muralidharan; Brielle Jones; Graham Allaway; Shyam S Biswal; Heidi M Mansour
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.996

10.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.